George Farmer
Stock Analyst at Scotiabank
(2.90)
# 1,756
Out of 5,093 analysts
70
Total ratings
44.74%
Success rate
0.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.35 | +640.74% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $74.08 | +79.54% | 4 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $2.04 | -70.59% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $23.08 | +103.64% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $19.98 | -14.91% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $5.72 | +109.79% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $3.11 | +189.39% | 4 | Apr 10, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $16.58 | +147.29% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $35.75 | +45.45% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $78 → $80 | $53.30 | +50.09% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $180.44 | +24.14% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $37.98 | +168.56% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $11.64 | -14.09% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $900.76 | -20.62% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $6.40 | +259.38% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $1.21 | +1,552.89% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $26.12 | +190.96% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $3.45 | +276.81% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $27.97 | +289.70% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $96.70 | -10.03% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.54 | +1,199.21% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.67 | +5,874.61% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $42.17 | -35.97% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.35
Upside: +640.74%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $74.08
Upside: +79.54%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $2.04
Upside: -70.59%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $23.08
Upside: +103.64%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $19.98
Upside: -14.91%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $5.72
Upside: +109.79%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $3.11
Upside: +189.39%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $16.58
Upside: +147.29%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $35.75
Upside: +45.45%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $53.30
Upside: +50.09%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $180.44
Upside: +24.14%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $37.98
Upside: +168.56%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $11.64
Upside: -14.09%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $900.76
Upside: -20.62%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $6.40
Upside: +259.38%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $1.21
Upside: +1,552.89%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $26.12
Upside: +190.96%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $3.45
Upside: +276.81%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $27.97
Upside: +289.70%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $96.70
Upside: -10.03%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.54
Upside: +1,199.21%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.67
Upside: +5,874.61%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $42.17
Upside: -35.97%